Abstract：Objective Study on the assessment value for the risk of the venous thromboembolism with serum coagulation factor Ⅷ in the patients of gastric carcinoma, and establish the medicine decide level. Methods Using the IL ACL TOP-700 blood coagulation analyzer assay FⅧ:A. Using receiver operating characteristic curve(ROC) to analyze the diagnosis performance of FⅧ:A, using Kaplan-Meier curve to implement survival analysis. Results The FⅧ:A level was higher than control in the patients group, the patients with VTE(within 3 months) was higher than the patients without VTE(P< 0.05). The level of FⅧ:A in different tumor stage showed that stage ⅢC>ⅢA and ⅢB>Ⅱ(P< 0.05), and there was no obviously difference between the stage Ⅱ and control(P> 0.05). The optimum cut-off point with FⅧ:A for VTE diagnosis was 125.5% in patients group, the diagnosis sensitivity was 95.2% and 71.0% for specificity. The cumulative probability of VTE was increased obviously within 90 days in the patients who FⅧ:A level over the cut-off value(Log-rank χ2=45.024, P=0.000). Conclusion The level of FⅧ:A was significantly increased in the patients with gastric carcinoma, and was associated with disease progression, there was the evaluation value in risk assessment of VTE.
欧阳淑娟,崔明. 血浆凝血因子Ⅷ活性测定评估胃癌患者静脉血栓栓塞风险*[J]. 实用预防医学, 2015, 22(8): 1001-1003.
OUYANG Shujuan, CUI Ming. To assay the serum factor Ⅷ activity to evaluate the risk of venous thromboembolism in patients of gastric carcinoma. , 2015, 22(8): 1001-1003.
[1] Jenkins PV, Rawley O, Smith OP, et al. Elevated factor Ⅷ levels and risk of venous thrombosis. Br J Haematol. 2012;157(6):653-663. [2] 陆培华,汤韵,李晨等.肿瘤坏死因子α-308位点基因多态性与胃癌易感的Mata分析[J].中华预防医学杂志,2010,44(3):209-214. [3] Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer.Blood. 2013;122(12):2011-2018. [4] Hanna DL, White RH, Wun T. Biomolecular markers of cancer-associated thromboembolism. Crit Rev Oncol Hematol. 2013;88(1):19-29. [5] Heidrich H, Konau E, Hesse P. Asymptomatic venous thrombosis in cancer patients a problem often overlooked. Results of a retrospective and prospective study.Vasa. 2009;38(2):160-166. [6] Kang MJ, Ryoo BY, Ryu MH, et al. Venous thromboembolism (VTE) in patients with advanced gastric cancer: an Asian experience. Eur J Cancer. 2012;48(4):492-500. [7] Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632-634. [8] Stein PD, Beemath A, Meyers FA, et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006;119:60-68. [9] Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials. Thromb Haemost. 2012;108(6):1042-1048. [10] Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer. 2011, 117: 1334-1349. [11] Vormittag R, Simanek R, Ay C, et al. High factor Ⅷ levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol. 2009;29(12):2176-2181. [12] Cosmi B, Legnani C, Cini M, et al. D-dimer and factor Ⅷ are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thromb Res. 2008; 122(5):610-617.
2015, Vol. 22 
